Inflammatory Bowel Disease in Activated PI3Kδ Syndrome: An Uncommon Complication of a Rare Condition
Abstract
1. Introduction
2. Case Report
3. Discussion
3.1. Activated Phosphoinositide-3-Kinase δ
3.2. Clinical Manifestations of APDS
3.3. Therapeutic Strategies in APDS
4. Conclusions
Author Contributions
Funding
Institutional Review Board Statement
Informed Consent Statement
Data Availability Statement
Acknowledgments
Conflicts of Interest
References
- Angulo, I.; Vadas, O.; Garçon, F.; Banham-Hall, E.; Plagnol, V.; Leahy, T.R.; Baxendale, H.; Coulter, T.; Curtis, J.; Wu, C.; et al. Phosphoinositide 3-kinase δ gene mutation predisposes to respiratory infection and airway damage. Science 2013, 342, 866–871. [Google Scholar] [CrossRef] [PubMed]
- Lucas, C.L.; Kuehn, H.S.; Zhao, F.; Niemela, J.E.; Deenick, E.K.; Palendira, U.; Avery, D.T.; Moens, L.; Cannons, J.L.; Biancalana, M.; et al. Dominant-activating germline mutations in the gene encoding the PI(3)K catalytic subunit p110δ result in T cell senescence and human immunodeficiency. Nat. Immunol. 2014, 15, 88–97. [Google Scholar] [CrossRef] [PubMed]
- Wentink, M.; Dalm, V.; Lankester, A.C.; van Schouwenburg, P.A.; Schölvinck, L.; Kalina, T.; Zachova, R.; Sediva, A.; Lambeck, A.; Pico-Knijnenburg, I.; et al. Genetic defects in PI3Kδ affect B-cell differentiation and maturation leading to hypogammaglobulineamia and recurrent infections. Clin. Immunol. 2017, 176, 77–86. [Google Scholar] [CrossRef] [PubMed]
- Preite, S.; Gomez-Rodriguez, J.; Cannons, J.L.; Schwartzberg, P.L. T and B-cell signaling in activated PI3K delta syndrome: From immunodeficiency to autoimmunity. Immunol. Rev. 2019, 291, 154–173. [Google Scholar] [CrossRef] [PubMed]
- Tangye, S.G.; Bier, J.; Lau, A.; Nguyen, T.; Uzel, G.; Deenick, E.K. Immune Dysregulation and Disease Pathogenesis due to Activating Mutations in PIK3CD—The Goldilocks’ Effect. J. Clin. Immunol. 2019, 39, 148–158. [Google Scholar] [CrossRef]
- Zhao, P.; Huang, J.; Fu, H.; Xu, J.; Li, T.; Zhang, X.; Meng, Q.; Zhang, L.; Tan, L.; Zhang, W.; et al. Activated phosphoinositide 3-kinase δ syndrome caused by PIK3CD mutations: Expanding the phenotype. Pediatr. Rheumatol. 2024, 22, 24. [Google Scholar] [CrossRef]
- Coulter, T.I.; Chandra, A.; Bacon, C.M.; Babar, J.; Curtis, J.; Screaton, N.; Goodlad, J.R.; Farmer, G.; Steele, C.L.; Leahy, T.R.; et al. Clinical spectrum and features of activated phosphoinositide 3-kinase δ syndrome: A large patient cohort study. J. Allergy Clin. Immunol. 2017, 139, 597–606.e4. [Google Scholar] [CrossRef]
- Patiroglu, T.; Akar, H.H.; Unal, E.; Ozdemir, M.A.; Karakukcu, M.; Patiroglu, T.E. Malignancies in Primary Immunodeficiencies: A Single Center Experience. Pediatr. Allergy Immunol. Pulmonol. 2015, 28, 47–54. [Google Scholar] [CrossRef]
- Elkaim, E.; Neven, B.; Bruneau, J.; Mitsui-Sekinaka, K.; Stanislas, A.; Heurtier, L.; Lucas, C.L.; Matthews, H.; Deau, M.C.; Sharapova, S.; et al. Clinical and immunologic phenotype associated with activated phosphoinositide 3-kinase δ syndrome 2: A cohort study. J. Allergy Clin. Immunol. 2016, 138, 210–218.e9. [Google Scholar] [CrossRef]
- Jamee, M.; Moniri, S.; Zaki-Dizaji, M.; Olbrich, P.; Yazdani, R.; Jadidi-Niaragh, F.; Aghamahdi, F.; Abolhassani, H.; Condliffe, A.M.; Aghamohammadi, A.; et al. Clinical, Immunological, and Genetic Features in Patients with Activated PI3Kδ Syndrome (APDS): A Systematic Review. Clin. Rev. Allergy Immunol. 2020, 59, 323–333. [Google Scholar] [CrossRef]
- Maccari, M.E.; Wolkewitz, M.; Schwab, C.; Lorenzini, T.; Leiding, J.W.; Aladjdi, N.; Abolhassani, H.; Abou-Chahla, W.; Aiuti, A.; Azarnoush, S.; et al. Activated phosphoinositide 3-kinase δ syndrome: Update from the ESID Registry and comparison with other autoimmune-lymphoproliferative inborn errors of immunity. J. Allergy Clin. Immunol. 2023, 152, 984–996.e10. [Google Scholar] [CrossRef] [PubMed]
- Cho, J.H.; Nicolae, D.L.; Ramos, R.; Fields, C.T.; Rabenau, K.; Corradino, S.; Brant, S.R.; Espinosa, R.; LeBeau, M.; Hanauer, S.B.; et al. Linkage and linkage disequilibrium in chromosome band 1p36 in American Chaldeans with inflammatory bowel disease. Hum. Mol. Genet. 2000, 9, 1425–1432. [Google Scholar] [CrossRef] [PubMed]
- Li, N.; Sun, W.; Zhou, X.; Gong, H.; Chen, Y.; Chen, D.; Xiang, F. Dihydroartemisinin protects against dextran sulfate sodium-induced colitis in mice through inhibiting the PI3K/AKT and NF-κB signaling pathways. Biomed. Res. Int. 2019, 2019, 1415809. [Google Scholar] [CrossRef] [PubMed]
- Oka, A.; Mishima, Y.; Liu, B.; Herzog, J.W.; Steinbach, E.C.; Kobayashi, T.; Plevy, S.E.; Sartor, R.B. Phosphoinositide 3-Kinase P110δ-Signaling Is Critical for Microbiota-Activated IL-10 Production by B Cells that Regulate Intestinal Inflammation. Cells 2019, 8, 1121. [Google Scholar] [CrossRef]
- Sogkas, G.; Adriawan, I.R.; Dubrowinskaja, N.; Atschekzei, F.; Schmidt, R.E. Chapter Four-Homeostatic and pathogenic roles of PI3Kδ in the human immune system. Adv. Immunol. 2020, 146, 109–137. [Google Scholar]
- Lougaris, V.; Cancrini, C.; Rivalta, B.; Castagnoli, R.; Giardino, G.; Volpi, S.; Leonardi, L.; La Torre, F.; Federici, S.; Corrente, S.; et al. Activated phosphoinositide 3-dinase delta syndrome (APDS): An update. Pediatr. Allergy Immunol. 2022, 33, 69–72. [Google Scholar] [CrossRef]
- Michalovich, D.; Nejentsev, S. Activated PI3 kinase delta syndrome: From genetics to therapy. Front. Immunol. 2018, 9. [Google Scholar] [CrossRef]
- Fruman, D.A.; Rommel, C. PI3K and cancer: Lessons, challenges and opportunities. Nat. Rev. Drug Discov. 2014, 13, 140–156. [Google Scholar] [CrossRef]
- Sriskantharajah, S.; Hamblin, N.; Worsley, S.; Calver, A.R.; Hessel, E.M.; Amour, A. Targeting phosphoinositide 3-kinase δ for the treatment of respiratory diseases. Ann. N. Y. Acad. Sci. 2013, 1280, 35–39. [Google Scholar] [CrossRef]
- Lindoso, L.; Deboni, M.; Barros Dorna, M.; Moschione Castro, A.P.; Pastorino, A.C.; Toma, R. P053 Activated PI3K-Delta Syndrome (APDS): A Monogenic Cause of VEO-IBD That Impacts on Treatment. Am. J. Gastroenterol. 2019, 114, S14. [Google Scholar] [CrossRef]
- Tessarin, G.; Rossi, S.; Baronio, M.; Gazzurelli, L.; Colpani, M.; Benvenuto, A.; Zunica, F.; Cardinale, F.; Martire, B.; Brescia, L.; et al. Activated phosphoinositide 3-kinase delta syndrome 1: Clinical and immunological data from an italian cohort of patients. J. Clin. Med. 2020, 9, 3335. [Google Scholar] [CrossRef] [PubMed]
- Swan, D.J.; Aschenbrenner, D.; Lamb, C.A.; Chakraborty, K.; Clark, J.; Pandey, S.; Engelhardt, K.R.; Chen, R.; Cavounidis, A.; Ding, Y.; et al. Immunodeficiency, autoimmune thrombocytopenia and enterocolitis caused by autosomal recessive deficiency of PIK3CD-encoded phosphoinositide 3-kinase δ. Haematologica 2019, 104, E483–E486. [Google Scholar] [CrossRef] [PubMed]
- Lougaris, V.; Piane, F.L.; Cancrini, C.; Conti, F.; Tommasini, A.; Badolato, R.; Trizzino, A.; Zecca, M.; De Rosa, A.; Barzaghi, F.; et al. Activated phosphoinositde 3-kinase (PI3Kδ) syndrome: An Italian point of view on diagnosis and new advances in treatment. Ital. J. Pediatr. 2024, 50, 103. [Google Scholar] [CrossRef] [PubMed]
- Van Rheenen, P.F.; Aloi, M.; Assa, A.; Bronsky, J.; Escher, J.C.; Fagerberg, U.L.; Gasparetto, M.; Gerasimidis, K.; Griffiths, A.; Henderson, P.; et al. The Medical Management of Paediatric Crohn’s Disease: An ECCO-ESPGHAN Guideline Update. J. Crohn’s Colitis 2021, 15, 171–194. [Google Scholar] [CrossRef]
- Ruemmele, F.M.; Garnier-Lengliné, H. Transforming growth factor and intestinal inflammation: The role of nutrition. Nestle Nutr. Inst. Workshop Ser. 2013, 77, 91–98. [Google Scholar]
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content. |
© 2024 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
Dargenio, V.N.; Rutigliano, V.; Martire, B.; Pigneur, B.; Dargenio, C.; Francavilla, R.; Cristofori, F. Inflammatory Bowel Disease in Activated PI3Kδ Syndrome: An Uncommon Complication of a Rare Condition. BioMed 2024, 4, 493-498. https://doi.org/10.3390/biomed4040037
Dargenio VN, Rutigliano V, Martire B, Pigneur B, Dargenio C, Francavilla R, Cristofori F. Inflammatory Bowel Disease in Activated PI3Kδ Syndrome: An Uncommon Complication of a Rare Condition. BioMed. 2024; 4(4):493-498. https://doi.org/10.3390/biomed4040037
Chicago/Turabian StyleDargenio, Vanessa Nadia, Vincenzo Rutigliano, Baldassarre Martire, Bénédicte Pigneur, Costantino Dargenio, Ruggiero Francavilla, and Fernanda Cristofori. 2024. "Inflammatory Bowel Disease in Activated PI3Kδ Syndrome: An Uncommon Complication of a Rare Condition" BioMed 4, no. 4: 493-498. https://doi.org/10.3390/biomed4040037
APA StyleDargenio, V. N., Rutigliano, V., Martire, B., Pigneur, B., Dargenio, C., Francavilla, R., & Cristofori, F. (2024). Inflammatory Bowel Disease in Activated PI3Kδ Syndrome: An Uncommon Complication of a Rare Condition. BioMed, 4(4), 493-498. https://doi.org/10.3390/biomed4040037